Unapproved Product Trial Data: To Post Or Not To Post On ClinicalTrials.gov?
This article was originally published in The Gray Sheet
Device makers say new clinical trial registration and results reporting requirements should be extended to trials of unapproved products only if the trials were stopped for safety reasons
You may also be interested in...
Rep. Rosa DeLauro's, D-Conn., hearing on the safety of GlaxoSmithKline's diabetes drug Avandia has ratcheted up the pressure on FDA to make broad reforms of its review structure, but the congresswoman has been careful not to urge a particular course of action for the agency
Device and drug firms must begin posting serious and frequent adverse event data from certain clinical trials on the National Institutes of Health's ClinicalTrials.gov database by September, NIH confirmed April 20
Device companies are not the only ones tripped up by the new ClinicalTrials.gov trial registration requirements, as FDA, NIH and others struggle to define what is and is not subject to the law